Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Vetbiolix
AddedMay 5, 2026
UpdatedMay 31, 2026
Vetbiolix

Vetbiolix

Veterinary biotech developing first-in-class pet therapeutics

HQ
LOOS, FR
Founded
2018
Overview
Compare
Fundraising
Employees
News
Website

Vetbiolix is a veterinary biotech company specializing in the clinical and pharmaceutical development of first-in-class oral small molecule drug candidates for companion animals, focusing on Osteoarthritis, Periodontitis, and Gut Motility Disorders.

Based in Loos, France, Vetbiolix leverages proven advances from human health biotech, licensing and developing drug candidates at clinical stages for veterinary applications. The company addresses unmet medical needs in the growing pet therapeutics market.

Vetbiolix - Similar Companies

Vetigenics logo

Vetigenics

vetigenics.com

AnimalBiome logo

AnimalBiome

animalbiome.com

PetVivo Holdings logo

PetVivo Holdings

petvivo.com

Aniluxx Biotechnology logo

Aniluxx Biotechnology

aniluxx.com

Vetherapy logo

Vetherapy

VetDC logo

VetDC

Veterinary Prime logo

Veterinary Prime

Animal Life Sciences logo

Animal Life Sciences

Vetmab Biosciences logo

Vetmab Biosciences

Invetx logo

Invetx

invetx.com

Skyline Vet Pharma logo

Skyline Vet Pharma

Animal Biosciences logo

Animal Biosciences

Companion Pharma logo

Companion Pharma

Animol Discovery logo

Animol Discovery

Curelab Veterinary logo

Curelab Veterinary

Vetbiolix - Quick Facts

Who are Vetbiolix's competitors?

Companies similar to Vetbiolix include Vetigenics, AnimalBiome, PetVivo Holdings and Aniluxx Biotechnology.

When was Vetbiolix founded?

Vetbiolix was founded in 2018.

Where is Vetbiolix's headquarters located?

Vetbiolix's headquarters is located in LOOS, FR.

When was Vetbiolix's last funding round?

Vetbiolix's most recent funding round was for $4M (USD) in December 2024.

How much has Vetbiolix raised to-date?

As of Dec 1, 2024, Vetbiolix has raised a total of $4M (USD).

How many employees does Vetbiolix have?

Vetbiolix has 7 employees as of May 5, 2026.

Vetbiolix - Classification

Industry
  • Biotechnology
Main Product
  • Biotech
  • Veterinary
  • Veterinary Therapeutics